| The company's sales in the quarter under review has however shown an increase of 4.67 per cent at Rs 286.5 crore as against Rs 273.7 crore of the corresponding quarter in 2005. |
| On a consolidated basis, the company registered 9 per cent growth in sales at Rs 413 crore during the second quarter of the financial year 2006. |
| However, profit after tax declined 18 per cent largely due to a 77 per cent increase in R&D expenditure and the expenses incurred on commercial commissioning of Wockhardt Biotech Park at Aurangabad, acompany release stated. |
| "We are investing significantly in research and manufacturing in India with a view to expand our US presence," Wockhardt chairman Habil Khorakiwala said. |
| "We entered the sterile injections market and also received our first approval for an NDDS drug in the US. |
| In India, we have reinforced our leadership in medical nutrition by acquiring Dumex India with its brands and marketing personnel," he added. |
| While the company's India business grew by 26 per cent in the first half of 2006, the second quarter performance of the company in the European market grew by 16 per cent. It's UK subsidairy-- Wockhardt UK had initiated a four-fold expansion in its Byetta cartridge manufacturing capacity, scheduled to be commissioned in September. |
| In the US the company had recieved four approvals during the first half. It had launched sterile cephalosporin ceftriaxone injection launched in the market earlier. |
| Wockhardt received its first NDDS approval, Divalproex Sodium delayed released tablets. More than 20 applications are pending with the US FDA for approval. |
| The company's biotech products "" Wosulin (recombinant insulin) and Wepox (erythropoietin) sales grew 35 per cent and 28 per cent respectively during the first half of the year. |
| Wockhardt consolidated its leadership in the Indian medical nutrition market by acquiring Dumex India with its heritage brands Farex and Protinex. |
Top Section
Explore Business Standard